PANE, CHIARA
 Distribuzione geografica
Continente #
NA - Nord America 582
EU - Europa 329
AS - Asia 145
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.071
Nazione #
US - Stati Uniti d'America 578
IT - Italia 200
CN - Cina 62
SG - Singapore 49
NL - Olanda 42
IE - Irlanda 22
DE - Germania 14
IN - India 13
CI - Costa d'Avorio 12
FI - Finlandia 12
BG - Bulgaria 11
GB - Regno Unito 10
CA - Canada 4
CH - Svizzera 4
HK - Hong Kong 4
JP - Giappone 4
PH - Filippine 4
SE - Svezia 4
TR - Turchia 4
UA - Ucraina 4
VN - Vietnam 4
MK - Macedonia 3
AP - ???statistics.table.value.countryCode.AP??? 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ES - Italia 1
EU - Europa 1
FR - Francia 1
IR - Iran 1
Totale 1.071
Città #
Chandler 143
Ashburn 62
Amsterdam 40
Naples 31
Singapore 27
Millbury 26
Beijing 25
Nanjing 24
Dearborn 18
Des Moines 18
Seattle 18
Napoli 17
Princeton 16
Nola 13
Boston 12
Sofia 11
Lawrence 10
Norwalk 10
Cava De' Tirreni 8
Gricignano di Aversa 7
Milan 7
Wilmington 7
Pune 6
Rome 6
Monteforte Irpino 5
Padova 5
Dong Ket 4
Fairfield 4
Hong Kong 4
Izmir 4
Lviv 4
Ottawa 4
Redwood City 4
Torre Annunziata 4
Washington 4
Battipaglia 3
Bitola 3
Dublin 3
General Mariano Alvarez 3
Houston 3
Montecorvino Pugliano 3
Santa Clara 3
Brusciano 2
Davis 2
Florence 2
Formia 2
Marsala 2
Parma 2
Phoenix 2
Pisa 2
Pompei 2
Portici 2
Sassari 2
Secunderabad 2
Shenyang 2
Tianjin 2
Turin 2
Whitby 2
Atlanta 1
Bern 1
Boardman 1
Caserta 1
Changchun 1
Eboli 1
Esslingen am Neckar 1
Guangzhou 1
Gunzenhausen 1
Hebei 1
Hefei 1
High Point 1
Indiana 1
Kolkata 1
Kronberg 1
Kunming 1
Lanzhou 1
Lappeenranta 1
Leawood 1
Lecce 1
London 1
Los Angeles 1
Madrid 1
Messina 1
Mumbai 1
Nanchang 1
Pasadena 1
Rochester 1
Sabz 1
San Giuseppe Vesuviano 1
San Jose 1
San Mateo 1
Sant'agata De' Goti 1
Sant'arpino 1
Scafati 1
Tamm 1
Torino 1
Verona 1
Woodbridge 1
Xian 1
Totale 701
Nome #
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 57
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 53
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 52
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 52
The use of medical-grade cannabis in patients non-responders to Nabiximols 51
Emotion Recognition and Psychological Comorbidity in Friedreich’s Ataxia 50
Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. 50
Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia 45
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 45
Prevalence and features of non-motor symptoms in Wilson's disease 45
Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests 43
Cerebellum and cognition in Friedreich ataxia: a voxel-based morphometry and volumetric MRI study 43
Peripheral markers of autophagy in polyglutamine diseases 42
Adult normative values for the PATA Rate Test 42
Screening for Fabry disease in a series of Parkinson’s disease patients and literature review 41
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 41
A randomized clinical trial of lithium in multiple system atrophy. 40
Mobitz type I and II atrioventricular blocks during fingolimod therapy 39
Fingolimod first dose safety in clinical practice. 30
The Multiple Faces of Spinocerebellar Ataxia type 2 27
Motor and non-motor features in Parkinson's Disease patients carrying GBA gene mutations 25
Dissociative Identity Disorder: Restoration of Executive Functions After Switch from Alter to Host Personality. 24
Correction to: Peripheral markers of autophagy in polyglutamine diseases (Neurological Sciences, (2018), 39, 1, (149-152), 10.1007/s10072-017-3156-6) 24
Othello syndrome in Parkinson's disease: a systematic review and report of a case series 24
Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis. 24
Conventional MRI findings in hereditary degenerative ataxias: a pictorial review 23
Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia 23
The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series 17
The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients 15
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response 13
Ataxia and Hypogonadism: a Review of the Associated Genes and Syndromes. 12
Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201) 9
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis 7
Brain Structure and Degeneration Staging in Friedreich Ataxia: Magnetic Resonance Imaging Volumetrics from the ENIGMA-Ataxia Working Group 7
A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A 5
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial 4
Nonvascular Parkinsonism in Fabry Disease: Results from Magnetic Resonance and Dopamine Transporter Imaging 4
Totale 1.148
Categoria #
all - tutte 4.785
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.785


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020122 26 16 0 0 5 4 21 5 4 26 14 1
2020/202142 5 0 1 9 0 4 2 2 8 0 6 5
2021/2022188 3 6 1 1 5 10 6 5 31 13 37 70
2022/2023344 36 37 13 19 40 33 9 28 58 52 16 3
2023/2024256 7 33 17 21 14 25 13 55 7 2 32 30
2024/202535 35 0 0 0 0 0 0 0 0 0 0 0
Totale 1.148